(News Bulletin 247) – Sanofi announces that it will present new data at the American Thoracic Society (ATS 2023) which will be held this year from May 19 to 24. These data demonstrate significant advancements in Dupixent and the broader respiratory pipeline.
A total of 17 abstracts present new data on Dupixent, itepekimab and the anti-IL-13/TSLP molecule NANOBODY in COPD and asthma.
Presentations on the experimental use of Dupixent in COPD include two late-breaking abstracts for the BOREAS trial.
Another late-breaking presentation shows mechanistic evidence in asthma for the first novel biologic targeting both the TSLP and IL-13 pathways.
‘We look forward to sharing results from Dupixent’s pivotal trial in COPD. We believe these findings, if approved, have the potential to transform the treatment paradigm for this devastating and debilitating disease,” said Naimish Patel, MD and Global Development Director, Immunology and Inflammation at Sanofi.
Copyright (c) 2023 News Bulletin 247. All rights reserved.
I have over 8 years of experience working in the news industry. I have worked as a reporter, editor, and now managing editor at 247 News Agency. I am responsible for the day-to-day operations of the news website and overseeing all of the content that is published. I also write a column for the website, covering mostly market news.
